Company
Company Overview
Production Bases
Business Philosophy
Qualifications & Honors
Sustainable Development (ESG)
Contact Us
Innovation
Innovation Pipeline
R&D Layout
Technology Platforms
Development and Cooperation
Research Achievements
Internationalization
Product Export
Intellectual Property Licensing
Products
Innovative Drugs
Launched Products
Upcoming Products
Service Center
News Center
Company News
Media Coverage
Join Us
Talent Development
Career Opportunities
English
English
中文
You may be searching for
Oncology Anti-Infection Digestive System Central Nervous System

Innovation

Focusing on the development of differentiated products in therapeutic areas such as oncology, anti-infection, and central nervous system.
Focusing on the development of differentiated products in therapeutic areas such as oncology, anti-infection, and central nervous system.
Oncology
Project
Target
Indication
PCC
IND
Phase I/II
Phase III
NDA
Launch
DN022150
KRAS G12D
Solid Tumor
Target
KRAS G12D
Indication
Solid Tumor
Anti-Infection
Project
Target
Indication
PCC
IND
Phase I/II
Phase III
NDA
Launch
GP681（Suraxavir Marboxil Tablets）
PA
Influenza
Target
PA
Indication
Influenza

Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Nature Medicine, 2025 Jan 7.

doi: 10.1038/s41591-024-03419-3

ClinicalTrials.gov registration: NCT05474755.

GP681 Dry Suspension
PA
Influenza
Target
PA
Indication
Influenza
KR24258
-
-
Target
-
Indication
-
Central Nervous System
Project
Target
Indication
PCC
IND
Phase I/II
Phase III
NDA
Launch
KR233
-
-
Target
-
Indication
-
KR232
-
-
Target
-
Indication
-
KR25102
-
-
Target
-
Indication
-
Other
Project
Target
Indication
PCC
IND
Phase I/II
Phase III
NDA
Launch
KR230109
-
-
Target
-
Indication
-